Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer

Exclusion Criteria

• •1. Inflammatory breast cancer
• •2. Inoperable disease that is judged very unlikely to be rendered operable by neo-adjuvant treatment
• •3. Known severe hypersensitivity to GnRHa treatment
• •4. Bilateral invasive breast cancer
• •5. Other serious illness or medical condition:
• •* congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias
• •* history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
• •* active uncontrolled infection
• •6. HRT within 4 weeks of starting treatment
• •7. Definite contra-indications for the use of corticosteroids.
• •8. Last 10 years with a history of other malignant tumor (except in the case of basal cell carcinoma or cervical carcinoma in situ, and where treatment consisted solely of resection)
• •9. Systemic metastatic (Tests for the diagnosis of systemic metastatic comply with the guideline in each institution)
• •10. Pregnant or breastfeeding women
• •11. Chronic oral treatment with corticosteroids unless initiated \> 6 months prior to study entry and at low dose (≤ 20 mg methylprednisolone or equivalent).